Xilio Therapeutics (XLO) Other Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics (XLO) has 6 years of Other Non-Current Liabilities data on file, last reported at $26.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $26.3 million; the trailing twelve-month figure through Mar 2026 stood at $26.3 million (changed N/A YoY), and the FY2025 full-year result was $29.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities fell to $26.3 million in Q1 2026, from $29.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $53.9 million in Q3 2025 to a low of $7000.0 in Q2 2023.
• A 4-year average of $14.9 million and a median of $91000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 61.86% in 2022, while the deepest fall reached 95.8% in 2022.
• Tracing XLO's Other Non-Current Liabilities over 4 years: stood at $45000.0 in 2022, then slumped by 84.44% to $7000.0 in 2023, then jumped by 422185.71% to $29.6 million in 2025, then declined by 11.16% to $26.3 million in 2026.
• Business Quant data shows XLO's Other Non-Current Liabilities at $26.3 million in Q1 2026, $29.6 million in Q4 2025, and $53.9 million in Q3 2025.